The Food and Drug Administration-approved antipsychotic drug trifluoperazine, a calmodulin antagonist, inhibits viral replication through PERK-eIF2α axis
Yizhi Mao, Ziyang Wang, Chen Yao and 5 more
Frontiers in Microbiology · 2022
doi:10.3389/fmicb.2022.979904 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
References49
49 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.